Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M630Revenue (TTM) $M150Net Margin (%)-8.9Altman Z-Score3.6
Enterprise Value $M500EPS (TTM) $-0.3Operating Margin %-9.3Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)-8.8Higher ROA y-yY
Price/Book5.010-y EBITDA Growth Rate %--Quick Ratio2.3Cash flow > EarningsY
Price/Sales4.25-y EBITDA Growth Rate %--Current Ratio2.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-6.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-10.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M44.6ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with VNDA

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

VNDA is held by these investors:



VNDA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kelly James PatrickSVP, CFO & Treasurer 2017-01-03Sell10,895$15.51-8.96view
Polymeropoulos Mihael HristosPresident and CEO 2017-01-03Sell23,330$15.48-8.79view
Baroldi PaoloSVP & Chief Medical Officer 2017-01-03Sell16,300$15.51-8.96view
Gulino Richard L.SVP, General Counsel & Sec. 2017-01-03Sell10,900$15.51-8.96view
Flynn James E 2016-09-23Sell1,120,461$16.56-14.73view
Flynn James E 2016-09-19Sell547,886$15.66-9.83view
Polymeropoulos Mihael HristosPresident and CEO 2016-01-04Sell21,353$8.9657.59view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2016-01-04Sell9,564$8.9657.59view
Baroldi PaoloSVP & Chief Medical Officer 2016-01-04Sell12,380$8.9657.59view
Flynn James E 2015-12-16Buy11,170$8.9757.41view

Quarterly/Annual Reports about VNDA:

News about VNDA:

Articles On GuruFocus.com
Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference May 01 2017 
Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017 Apr 13 2017 
Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors Mar 31 2017 
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 

More From Other Websites
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May... May 22 2017
ETFs with exposure to Vanda Pharmaceuticals, Inc. : May 5, 2017 May 05 2017
Edited Transcript of VNDA earnings conference call or presentation 2-May-17 8:30pm GMT May 05 2017
Vanda Pharmaceuticals expands into cystic fibrosis, blood cancer May 04 2017
Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 May 04 2017
Vanda reports 1Q loss May 02 2017
Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results May 02 2017
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call May 02 2017
Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference May 01 2017
Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : April 20, 2017 Apr 20 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : April... Apr 19 2017
Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017 Apr 13 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : March... Mar 31 2017
Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors Mar 29 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : March... Mar 07 2017
Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences Mar 06 2017
Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 Feb 22 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US :... Feb 21 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat